Nanotein Exhibits at ISCT 2022

Nanotein presents ISCT exhibit

Curtis Hodge, CEO & Co-Founder of Nanotein, along with Zach Imam, Scientist II, presented Nanotein’s first exhibit at the ISCT 2022 conference in San Francisco, California. Throughout the conference from May 4th to 6th, they received lots of interest from potential beta-testers, collaborators, partners, and future customers!

Zach Imam, PhD

Zach Imam Scientist II at Nanotein Technologies Headshot 1

  Zach is a scientific leader at Nanotein. His expertise in lipid nanoparticle development, protein biophysics, and rheological characterization is instrumental to Nanotein’s progress towards advancing their protein-derived nanoparticle for CAR-T cell activation and expansion. Zach received his PhD in Biomedical Engineering at the University of Texas at Austin and completed a Post-Doctoral Fellowship at […]

Team Outing

Nanotein Technologies Team Outing

Members from Nanotein and their strategic partners, Polaris, met for a teambuilding lunch and photos! From left to right: Patrick Carney, Greg Hura, Zach Imam, Curtis Hodge, Chris Huxsoll, and Jose Ortiz.

Nanotein Forms Strategic Partnership & Secures Funding

Polaris Group Strategic Partner Logo

Nanotein and Polaris Group, a developer of novel treatments for cancer, announced they have entered into a strategic partnership to advance Nanotein’s protein-based solutions for superior cellular therapy manufacturing. Based on a proprietary platform technology, Nanotein’s first product is a superior T cell activation and expansion reagent for use in the biomanufacturing of CAR-T cell […]

Nanotein Chosen as a Top Emerging Biotech by QB3

Curtis Hodge CEO at QB3 Pitch Summit 2019

“Eighty-five companies applied. From these, a judging panel drawn from industry and the investing community selected a cohort of 12: four “emerging,” or earlier-stage, startups, and eight who had advanced their technologies further along the path to market.” – QB3/Cision PR Newswire   Nanotein Chosen as a Top Emerging Biotech by QB3 at Their Biotech/Biopharma […]